As a world-leading biopharmaceutical company, Creative Biolabs offers a full range of services to help you develop a novel and effective therapy for narcolepsy. Our in-home scientists combine their extensive knowledge of narcolepsy with the company’s powerful drug development platforms to support monoclonal antibody development, bispecific antibody development, and cell-based therapy development for narcolepsy treatment.
Narcolepsy is a long-term neurological sleep disorder characterized by excessive daytime sleepiness. It is a rare disease with a world prevalence threshold of between 25 and 50 cases per 100,000 people. Narcolepsy is divided into two types: Type 1 and Type 2. The former is the most common. People with the former have a symptom called cataplexy which is a sudden, temporary loss of muscle tone, while people with the latter do not exhibit a cataplexy symptom. The cause of narcolepsy is not clear and it may be caused by several distinct factors. Genetics is a primary factor that has been strongly implicated in the development of narcolepsy. Specific variations in HLA genes have been revealed a strong association with the presence of narcolepsy. Besides, narcolepsy is caused by the loss of orexin-releasing neurons within the lateral hypothalamus which is caused by an autoimmune disorder. In narcolepsy, the immune system mistakenly attacks orexin-releasing neurons.
There is no specific cure for narcolepsy, but some treatments can ease the symptoms. Medical treatment for narcolepsy typically includes stimulants, antidepressants, Sodium oxybate, selective serotonin reuptake inhibitors (SSRIs) or serotonin, and norepinephrine reuptake inhibitors (SNRIs). These drugs are used to reduce excessive daytime sleepiness and/or reduce the other symptoms of narcolepsy.
Furthermore, Hypocretin-based therapies, such as direct use of hypocretin peptides, hypocretin agonists, hypocretin gene therapy, hypocretin neuron transplantation, and immunotherapy are part of the research projects for the development of new treatments in narcolepsy. Several studies have reported orexin gene therapy can restore orexin signaling in a mouse model of narcolepsy and improve the symptoms of narcolepsy such as the long bouts of wakefulness and the timing of rapid eye movement sleep. Replacement therapy using orexin receptor agonists (such as TAK-994) also provides a promising novel therapeutic option for narcolepsy. Immune therapies such as immunoglobulins (IVIg) have been shown to reduce the destruction of orexin-releasing neurons in some selected patients. Further randomized controlled trials are required to investigate the beneficial potential of IVIg in narcolepsy.
We are the expert in the field of drug discovery for narcolepsy. Leveraging advanced and well-established antibody development, we provide a full range of therapeutic antibody development services for narcolepsy treatment. We also take advantage of our extensive expertise in cell therapy to support the development of orient-modified cells. If you are studying novel drugs for treating narcolepsy, please don’t hesitate to contact us to discuss your project. We will become your reliable partner.
For Research Use Only | Not For Clinical Use
Contact us
USA
Creative Biolabs is a world-leading CRO that is skilled in developing novel therapies,
especially in antibody and cell therapy for autoimmune diseases.
Copyright © 2024 Creative Biolabs. All Rights Reserved.
